Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 50 of 158 results for urinary tract infections

  1. Urinary tract infection (recurrent): antimicrobial prescribing (NG112)

    This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

  2. Urinary tract infection in under 16s: diagnosis and management (NG224)

    This guideline covers diagnosing and managing first or recurrent upper or lower urinary tract infection (UTI) in babies, children and young people under 16. It aims to achieve more consistent clinical practice, based on accurate diagnosis and effective management. It does not cover babies, children and young people with urinary catheters in situ, neurogenic bladders, significant pre-existing urinary tract disorders (uropathies), underlying renal disease or immunosuppression, or recurrent UTI in sexually active girls and young women under 16. It also does not cover babies, children and young people in intensive care units.

  3. Urinary tract infection (catheter-associated): antimicrobial prescribing (NG113)

    This guideline sets out an antimicrobial prescribing strategy for catheter-associated urinary tract infection in children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

  4. Urinary incontinence in neurological disease: assessment and management (CG148)

    This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

  5. Urinary tract infections in adults (QS90)

    This quality standard covers diagnosing and managing urinary tract infections in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

  6. Lower urinary tract symptoms in men: management (CG97)

    This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.

  7. Urinary tract infection in children and young people (QS36)

    This quality standard covers diagnosing and managing urinary tract infection in infants, children and young people (under 16). It includes new and recurrent infections of the upper or lower urinary tract. It describes high-quality care in priority areas for improvement.

  8. Prostatitis (acute): antimicrobial prescribing (NG110)

    This guideline sets out an antimicrobial prescribing strategy for acute prostatitis. It aims to optimise antibiotic use and reduce antibiotic resistance.

  9. Infection prevention and control (QS61)

    This quality standard covers preventing and controlling infection in adults, young people and children receiving healthcare in primary, community and secondary care settings. It includes preventing healthcare-associated infections that develop because of treatment or from being in a healthcare setting. It describes high-quality care in priority areas for improvement.

  10. Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

  11. Urinary incontinence and pelvic organ prolapse in women: management (NG123)

    This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.

  12. Acute kidney injury: prevention, detection and management (NG148)

    This guideline covers preventing, detecting and managing acute kidney injury in children, young people and adults. It aims to improve assessment and detection by non-specialists, and specifies when people should be referred to specialist services. This will improve early recognition and treatment, and reduce the risk of complications in people with acute kidney injury.

  13. Urinary tract infection (lower): antimicrobial prescribing (NG109)

    This guideline sets out an antimicrobial prescribing strategy for lower urinary tract infection (also called cystitis) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

  14. Urinary tract infection

    All NICE products on urinary tract infection. Includes any guidance, advice and quality standards.

  15. Bladder cancer: diagnosis and management (NG2)

    This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.

  16. Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.

  17. Pneumonia: diagnosis and management (NG250)

    This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

  18. Cerebral palsy in under 25s: assessment and management (NG62)

    This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

  19. Bedwetting in under 19s (CG111)

    This guideline covers assessing and treating bedwetting in people aged under 19. It aims to reduce bedwetting and the distress this causes by explaining what to ask in an assessment, what advice to provide, and which treatments are effective.

  20. Caesarean birth (NG192)

    This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.

  21. Suspected cancer: recognition and referral (NG12)

    This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.

  22. Patient decision aids

    glucose (HbA1c) target Bisphosphonates for treating osteoporosis Digestive tract conditions Long term heartburn treatment Gynaecological...

  23. Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)

    This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.

  24. Sore throat (acute): antimicrobial prescribing (NG84)

    This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.

  25. Fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction (IPG205)

    Evidence-based recommendations on fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction. This involves inserting a tube with a flexible camera through small cuts in the mother's abdomen to identify and open any blockage.

  26. Memokath 051 Ureter stent for ureteric obstruction (HTG651)

    Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.

  27. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

  28. Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG625)

    Evidence-based recommendations on transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves using heated water vapour to destroy some of the prostate tissue.

  29. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition (CG32)

    This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home. It offers advice on how oral, enteral tube feeding and parenteral nutrition support should be started, administered and stopped. It aims to support healthcare professionals identify malnourished people and help them to choose the most appropriate form of support.

  30. URO17 for detecting bladder cancer (MIB250)

    NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .

  31. Prostate cancer: diagnosis and management (NG131)

    This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.

  32. Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia (IPG798)

    Evidence-based recommendations on transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. This involves using laser energy to destroy some of the prostate tissue.

  33. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.

  34. UroShield for preventing catheter-associated urinary tract infections (HTG620)

    Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.

  35. Healthcare-associated infections: prevention and control in primary and community care (CG139)

    This guideline covers preventing and controlling healthcare-associated infections in children, young people and adults in primary and community care settings. It provides a blueprint for the infection prevention and control precautions that should be applied by everyone involved in delivering NHS care and treatment.

  36. Laparoscopic nephrectomy (including nephroureterectomy) (IPG136)

    Evidence-based recommendations on laparoscopic nephrectomy (including nephroureterectomy). This involves making small incisions (keyhole surgery) to remove the damaged kidney, or kidney, ureter and surrounding tissue.

  37. Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia (IPG654)

    Evidence-based recommendations on reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia. This involves inserting a piece of mesh to strengthen the abdominal wall.

  38. Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment (HTG674)

    Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.

  39. Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

  40. Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)

    Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated

  41. Older people in day and residential care:- How effective are interventions in day and residential care for older people that aim to prevent infection and to reduce antimicrobial resistance?

    interventions in day and residential care for older people that aim to prevent infection and to reduce antimicrobial resistance? Any...

  42. Urinary tract infection (lower). Patient decision aid on cystitis: taking an antibiotic

    your gut getting into your bladder. Cystitis is also called lower urinary tract infection or UTI. Sometimes...

  43. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (HTG386)

    Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).

  44. Skin involvement in systemic sclerosis: rituximab (ES7)

    Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

  45. Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.

  46. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  47. SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)

    Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.

  48. Fever in under 5s: assessment and initial management (NG143)

    This guideline covers the assessment and early management of fever with no obvious cause in children aged under 5. It aims to improve clinical assessment and help healthcare professionals diagnose serious illness among young children who present with fever in primary and secondary care.